Rumor Has Terumo Eyeing Abbott's Cardio Biz
Terumo is reportedly eyeing a nearly $1.5 billion deal for Abbott‘s (NYSE:ABT) cardiovascular device business.
The ¥150 billion deal, if consummated, would be part of Abbott’s move to shed assets and consolidate pending the close of its $25 billion merger with St. Jude Medical (NYSE:STJ), according to Japan’s Nikkei business journal. Earlier this month, Abbott announced plans to deal its medical optics business to Johnson & Johnson (NYSE:JNJ) for $4.3 billion.
The ¥150 billion deal, if consummated, would be part of Abbott’s move to shed assets and consolidate pending the close of its $25 billion merger with St. Jude Medical (NYSE:STJ), according to Japan’s Nikkei business journal. Earlier this month, Abbott announced plans to deal its medical optics business to Johnson & Johnson (NYSE:JNJ) for $4.3 billion.